| P2093 | author name string | S Weinmann | |
| | A Heinz | |
| | V Aderhold | |
| | C Hägele | |
| P2860 | cites work | Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? | Q22242820 |
| | Early intervention for psychosis | Q24236296 |
| | Family intervention for schizophrenia | Q24243838 |
| | Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies | Q24626182 |
| | Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys | Q24654374 |
| | A review of MRI findings in schizophrenia | Q24657354 |
| | Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Q28266069 |
| | Dopaminergic dysfunction in schizophrenia: salience attribution revisited. | Q30475711 |
| | How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: the roles of in vivo serotonin transporter expression and amygdala structure | Q30511878 |
| | Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia | Q30529640 |
| | Effects of psychoactive substances in schizophrenia -- findings of structural and functional neuroimaging | Q30583762 |
| | Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia | Q30994462 |
| | What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia | Q31147040 |
| | Compounded brain volume deficits in schizophrenia-alcoholism comorbidity | Q33186290 |
| | Effects of antipsychotics on brain structure | Q33239807 |
| | Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings | Q33425487 |
| | The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review. | Q33494667 |
| | A systematic review of the effects of antipsychotic drugs on brain volume | Q33525203 |
| | Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 |
| | Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies | Q33860665 |
| | The pharmacotherapy of neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in Berlin | Q33887166 |
| | The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys | Q33985626 |
| | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 |
| | Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis | Q33990440 |
| | Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse | Q33996824 |
| | G72 influences longitudinal change in frontal lobe volume in schizophrenia | Q34013842 |
| | Antipsychotic dosing: how much but also how often? | Q34023214 |
| | Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders | Q34048584 |
| | Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia | Q34127541 |
| | Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia | Q34167569 |
| | Brain volumes in relatives of patients with schizophrenia: a meta-analysis | Q48252424 |
| | Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study | Q48258798 |
| | Volume reduction of the left planum temporale gray matter associated with long duration of untreated psychosis in schizophrenia: a preliminary report | Q48262556 |
| | Cigarette smoking and progressive brain volume loss in schizophrenia | Q48273078 |
| | Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. | Q48286419 |
| | Superior temporal gyrus volume in antipsychotic-naive people at risk of psychosis | Q48287856 |
| | The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse | Q48295666 |
| | Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. | Q48373158 |
| | Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment | Q48373874 |
| | Is olanzapine a brain-sparing medication? | Q48377357 |
| | Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia | Q48380695 |
| | Neuroleptics in progressive structural brain abnormalities in psychiatric illness | Q48395659 |
| | Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats | Q48435138 |
| | Brain volume changes in first-episode schizophrenia: a 1-year follow-up study | Q48452819 |
| | Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM. | Q48484501 |
| | Gray matter morphology and the level of functioning in one-year follow-up of first-episode schizophrenia patients | Q48496567 |
| | A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia. | Q48499474 |
| | A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures | Q48519543 |
| | Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics | Q48565571 |
| | Gray matter abnormalities associated with duration of untreated psychosis | Q48666871 |
| | Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation | Q48714094 |
| | Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder | Q48825061 |
| | Grey matter changes over time in high risk subjects developing schizophrenia | Q48916191 |
| | Volumes of brain structures in twins discordant for schizophrenia. | Q49079281 |
| | Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment | Q49143510 |
| | Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. | Q50181509 |
| | Diazepam treatment of early signs of exacerbation in schizophrenia. | Q51475042 |
| | Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis | Q51829586 |
| | Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. | Q51886500 |
| | Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. | Q51900011 |
| | Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. | Q51903646 |
| | Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. | Q51918187 |
| | [Structural and functional brain changes in schizophrenic disorders. Indications of early neuronal developmental disturbances?]. | Q51964590 |
| | Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. | Q51964827 |
| | Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. | Q53080297 |
| | Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. | Q55053712 |
| | Schizophrenia | Q55868331 |
| | Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries | Q57470966 |
| | Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine | Q57834282 |
| | "Extended" Antipsychotic Dosing | Q59739357 |
| | Brain Volume Changes After Withdrawal of Atypical Antipsychotics in Patients With First-Episode Schizophrenia | Q60610017 |
| | Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia | Q63894076 |
| | Neuroleptic withdrawal in schizophrenic patients | Q72583780 |
| | Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment | Q73008054 |
| | Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up | Q73090428 |
| | Brain and ventricle instability during psychotic episodes of the schizophrenias | Q73924945 |
| | Gray matter volume differences and the effects of smoking on gray matter in schizophrenia | Q81341337 |
| | Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. | Q34174069 |
| | Clinical relevance of findings in trials of antipsychotics: systematic review | Q34180797 |
| | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis | Q34213209 |
| | Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review | Q34253069 |
| | Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. | Q34271687 |
| | Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. | Q34295212 |
| | Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. | Q34337272 |
| | Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. | Q34351095 |
| | Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study | Q34392600 |
| | Antipsychotic drug effects on brain morphology in first-episode psychosis | Q34408860 |
| | Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression | Q34415969 |
| | Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. | Q34415975 |
| | Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys | Q34576434 |
| | Dopaminergic dysfunction in alcoholism and schizophrenia--psychopathological and behavioral correlates | Q34579920 |
| | Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder | Q34603527 |
| | Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial | Q34616402 |
| | Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization | Q34646095 |
| | Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia | Q34706991 |
| | How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials | Q34733976 |
| | Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. | Q34899462 |
| | Time-lapse mapping of cortical changes in schizophrenia with different treatments | Q35015837 |
| | A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia | Q36013286 |
| | Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? | Q36352679 |
| | Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia | Q36395044 |
| | Reduced gray matter volume in psychotic disorder patients with a history of childhood sexual abuse | Q36518172 |
| | Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. | Q36929181 |
| | The nature of dopamine dysfunction in schizophrenia and what this means for treatment | Q37062793 |
| | The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia | Q37075127 |
| | Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects | Q37131066 |
| | Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia | Q37155942 |
| | Polypharmacy with second-generation antipsychotics: a review of evidence | Q37341522 |
| | Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study | Q37435199 |
| | Young people at ultra high risk for psychosis: a research update. | Q37826237 |
| | Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis | Q37837288 |
| | Gray matters!--mapping the transition to psychosis | Q37937785 |
| | Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms | Q37966430 |
| | Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents | Q37967965 |
| | Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia | Q38371590 |
| | "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial | Q38499518 |
| | Neuroleptic withdrawal in schizophrenic patients. A review of the literature | Q40602444 |
| | Longitudinal study of brain morphology in first episode schizophrenia | Q40718665 |
| | One hundred years of alcoholism: the Twentieth Century | Q40777503 |
| | Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study | Q42169712 |
| | Maintenance medication for schizophrenia and schizoaffective patients | Q42635911 |
| | Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits | Q43043680 |
| | Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation | Q43147452 |
| | Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory | Q43657595 |
| | Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients | Q43723165 |
| | Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. | Q43733387 |
| | Family interventions in early psychosis: specificity and effectiveness | Q43817818 |
| | Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient | Q44278018 |
| | Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus | Q44793041 |
| | Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol | Q44914407 |
| | Structural brain alterations in subjects at high-risk of psychosis: a voxel-based morphometric study | Q44951583 |
| | Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method | Q45295760 |
| | Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. | Q45307345 |
| | Changes in cortical thickness during the course of illness in schizophrenia. | Q45927962 |
| | Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine | Q46310735 |
| | D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats | Q46439909 |
| | Cerebral cortical gray expansion associated with two second-generation antipsychotics | Q46578655 |
| | Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia | Q46693287 |
| | Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery | Q46737022 |
| | Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia | Q46974035 |
| | Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients | Q47951468 |
| | Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood | Q48122360 |
| | White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment | Q48148097 |
| | Regional brain morphology and duration of illness in never-medicated first-episode patients with schizophrenia. | Q48188116 |
| | Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study | Q48188142 |
| P433 | issue | 3 | |
| P304 | page(s) | 302-323 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | Der Nervenarzt | Q15446312 |
| P1476 | title | [Frontal brain volume reduction due to antipsychotic drugs?] | |
| P478 | volume | 86 | |